@FiercePharma: Top-read on FP Tues: Big Pharma doesn't win the margin stakes. That's Jazz, Celgene, Regeneron and Alexion. Report | Follow @FiercePharma
@TracyStaton: Been on vacay? @FiercePharma's top August news so far: Pfizer faces growing legal threat over Lipitor. More | Follow @TracyStaton
@EricPFierce: FDA warning letter for India's Marck Biosciences lays out in vivid detail why it banned it plant. Article | Follow @EricPFierce
@CarlyHFierce: Merck taps celeb chef to deliver diabetes message to Hispanics. Story | Follow @CarlyHFierce
> It's a game of real estate musical chairs for Bristol-Myers Squibb ($BMY), Amgen ($AMGN) and an unidentified biotech, all seeking big blocks of space in Cambridge, MA's Kendall Square area. Report
> Ranbaxy Laboratories, the embattled Indian generics maker, lost another two senior managers, including global HR chief Sandeep Girotra. Report
> Eisai asked European regulators to approve a new use for its seizure drug Fycompa, as an add-on treatment for Primary generalized tonic-clonic seizures. Release
> A shake-up at the top of drugstore giant Walgreen ($WAG) followed a misguided estimate for Medicare Part D revenues, which ended up forcing the company to cut its 2014 forecast by more than $1 billion. Report (sub. req.)
> Jordan-based Hikma Pharmaceuticals cut its 2014 revenue forecast thanks to unrest in the Middle East, which is interfering with sales. Report
Medical Device News
@FierceMedDev: VC Rock Health partners with Abbott, expands digital health portfolio. Story | Follow @FierceMedDev
@StacyALawrence: Abbott gets $20M from DoD to develop portable concussion test. More | Follow @StacyALawrence
@VarunSaxena2: ICYMI: FDA targets off-label use of intranasal splint, with safety alert and Class I recall notice. Article | Follow @VarunSaxena2
@EmilyWFierce: Scientists at Biomeme developing a portable, real-time PCR machine that runs lab tests through a smartphone. Story via Wired | Follow @EmilyWFierce
> Boston Sci to develop two new guidewires with cardiological indications by 2015. Story
> Survey says people want neurological diagnosis, regardless of cure. More
> ConvaTec weighs plans for inversion deal amid rumors of 2015 sale. Article
Biotech News
@FierceBiotech: Sanofi wins FDA's blessing for an oral Gaucher drug. News | Follow @FierceBiotech
@JohnCFierce: Top trending story, 2 days now: Novo chief Sorensen preps for showdown as Lilly's dulaglutide nears diabetes market. Report | Follow @JohnCFierce
@DamianFierce: $FOLD CEO on positive new migalastat data, next-gen Fabry treatment and the importance of perseverance. Report | Follow @DamianFierce
@EmilyMFierce: Viral inducers plus antibodies thwart latent HIV in mice. FierceBiotech Research story | Follow @EmilyMFierce
> AstraZeneca's new antibiotic comes through in Phase III. Item
> Bristol-Myers, Celgene plan to match an immuno-oncology star with a rising chemotherapy. Story
> Could buying Salix get Valeant off of Allergan's scent? More
Drug Delivery News
> Hydrogel enables longer graft survival in hand, leg transplant patients. Article
> Russian scientists close in on drug-delivering nanorobots. Story
> Study finds blood-brain barrier opening can be controlled, enabling enhanced drug delivery. More
> Mist formulation of Boehringer Ingelheim's COPD inhaler gets advisory committee nod. Story
> Scientists uncover new drug delivery method using nanosecond lasers and carbon nanotubes. Article
Diagnostics News
> Blood test for drug-resistant malaria strain shows promise. Report
> Two tests better than one to spot harmful mold infection. Story
> Cancer Genetics boosts Medicare coverage for DNA-based cancer Dx. More
> LabCorp jumps into prenatal Dx market already packed with rivals. Story
> Investors become ambivalent to Biocept's Dx commercialization plans. Article
Pharma Marketing News
> Celgene cost-sharing deal sways NICE to greenlight new Revlimid use. News
> When is 5 years not 5 years? When it's the FDA counting, Eisai claims. Report
> AbbVie aims to truck ahead with hep C testing promo campaign. More
> Hardest-charging drugs this year? They're not just Sovaldi and Olysio. Story
> Skeptical U.K. watchdogs decide to back Gilead's hep C star Sovaldi. Article
And Finally... Does your dog need training to run with you? No, but a good diet doesn't hurt. Report